No profile photo available

Adam S. DuVall, MD, MPH

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Hematology & Hematologic Malignancies

Academic Office Information

adam.duvall@hci.utah.edu

Board Certification

  • American Board of Internal Medicine (Internal Medicine)
  • American Board of Pediatrics (Pediatrics)
  • American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
  • American Board of Internal Medicine (Sub: Medical Oncology)

Education History

Undergraduate University of Notre Dame
 BS
Graduate Training Case Western Reserve University
 MPH
Professional Medical Case Western Reserve University School of Medicine
 MD
Residency University of Michigan Health
 Resident
Fellowship Oregon Health & Science University
 Fellow
Fellowship OHSU Doernbecher Children's Hospital
 Fellow

Selected Publications

Journal Article

  1. DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani AS, Aljurf M, Audino AN, Benitez L, Deeter A, Dworkin E, Hiltbrand OS, Isenalumhe LL, Li L, Miller-Chism CN, Mozessohn L, Ng AP, Pu JJ, Shafer D, Vargas Madueno F, Viny AD, Wadhwa A, Yang J, Zarnegar-Lumley S, Mai HJ, Kanaan G, Sereda Y, Saldanha IJ, Balk EM, Stock WA, Wolfson J (2026). ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood advances,
  2. Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin HY, Ors A, Davis BA, Nikolova O, Bresciani E, Diemer J, Craft K, Menezes AC, Merguerian M, Chong S, Calvo KR, Deuitch NT, Glushakow-Smith S, Gritsman K, Godley LA, Horwitz MS, Keel S, Castilla LH, Demir E, Mohammed H, Liu P, Agarwal (2025). Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder. Science translational medicine, 17(780), eadn9832.
  3. Greenzang KA, Montgomery KE, DuVall A, Roth ME, Krailo M, Nuño MM, Renfro L, DelRocco N, Doski J, Kelly K, Castellino SM, McNeer J, O'Brien MM, Reed D, Janeway K, Hinds PS, Zupanec S, Parsons S (2025). Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. Journal of the National Cancer Institute, 117(9), 1764-1773.
  4. Madero-Marroquin R, Cannova J, Dworkin E, Wesevich A, Roloff GW, Saygin C, Nawas MT, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Drazer MW, Patel A (2025). Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem, 6(3), e70078.
  5. Zhang A, Chen M, Brandon R, Currin-McCulloch J, Liu X, Cheladyn B, Ferrell B, Jones B, Zebrack B, DuVall A (2025). The Current State of Palliative Care Research for Adolescents and Young Adults With Cancer: A Systematic Review and Meta-Thematic Analysis of Empirical Literature. Psycho-oncology, 34(7), e70228.
  6. DaSilva B, Darwin A, Zhang A, Vyas RD, Russell K, Gilbert JS, Tan V, Feldt S, Johnston H, Liang EC, DuVall AS, Liedtke M, Stock W, Cassaday RD, Schwartz M, Leonard JT, Muffly LS, Luskin M (2025). Real-world performance of the CALGB 10403 regimen in young adults in the United States. Blood neoplasia, 2(3), 100111.
  7. Hantel A, Senay E, Hlubocky FJ, Walsh TP, Johnston H, Cronin A, DuVall AS, Revette A, Nava-Coulter B, Siegler M, Richie C, Abel G (2025). The ethics of climate change and health-care delivery: a national survey of US-based physicians. The Lancet. Planetary health, 9(8), 101289.
  8. Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld AK, Anderson C, Lin C, Moreno Vanegas YA, Badar T, Coltoff A, Knepper TC, Ozkaya N, Youshanlouei HR, Cetin S, Patel AA, DuVall AS, Drazer MW, Wang P, Tjota M, Segal JP, Venkataraman G, Gurbuxani S, Cheng JX, Arber DA, Larson RA, Odenike O, Webster J, Shah B, Stock W, Saygin (2025). Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood cancer journal, 15(1), 138.
  9. Moerdler S, DuVall AS, Hayes-Lattin B, Grimes A, Prasad PK, Molina JC, Monga V, Freyer DR, Roth M (2024). Gaps in Adolescent and Young Adult Cancer Education in Oncology Fellowship Training. Journal of adolescent and young adult oncology, 13(1), 97-104.
  10. Madero-Marroquin R, DuVall AS, Saygin C, Wang P, Gurbuxani S, Larson RA, Stock W, Patel A (2024). Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. British journal of haematology, 204(4), 1238-1242.
  11. Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin (2024). Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood advances, 8(1), 164-171.
  12. Demedis J, Bingen K, Cherven B, Frederick NN, Freyer DR, Levine J, Bhutada JS, Quinn GP, Bober SL, DuVall A (2024). Development of a Patient-Reported Sexual Health Outcomes Battery for Use in Adolescent and Young Adult Cancer Clinical Trials. Journal of adolescent and young adult oncology, 13(3), 369-373.
  13. Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer M (2024). Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica, 109(11), 3739-3744.
  14. Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow M (2024). Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica, 109(11), 3533-3542.
  15. Collins J, Duvall A, Dworkin E, Castiel (2024). A systematic approach to the management of menses prophylaxis and suppression in pre-menopausal hematologic cancer patients. Journal of oncology pharmacy practice, 30(7), 1259-1267.
  16. O'Keefe K, Chen M, Lesser KJ, DuVall AS, Dils A (2024). Treating Mental Health and Quality of Life in Older Cancer Patients with Cognitive Behavioral Therapy: A Systematic Review and Meta-Analysis. International journal of environmental research and public health, 21(7),
  17. Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow (2024). Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. American journal of hematology, 99(12), 2388-2391.
  18. Madero-Marroquin R, Hunter RW, Saygin C, Johnston H, DuVall AS, Rahmani Youshanlouei H, Osei C, Shah S, Stock W, Gurbuxani S, Patel A (2024). CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem, 6(1), e1076.
  19. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer M (2023). Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica, 108(8), 2234-2239.
  20. Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow M (2023). Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia, 37(4), 799-806.
  21. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah (2023). Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer, 129(6), 934-945.
  22. Ito D, Feng C, Fu C, Kim C, Wu J, Epstein J, Snider JT, DuVall A (2023). Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis. Expert review of pharmacoeconomics & outcomes research, 23(7), 773-787.
  23. Saygin C, Giordano G, Shimamoto K, Eisfelder B, Thomas-Toth A, Venkataraman G, Ananthanarayanan V, Vincent TL, DuVall A, Patel AA, Chen Y, Tan F, Anthony SP, Chen Y, Shen Y, Odenike O, Teachey DT, Kee BL, LaBelle J, Stock (2023). Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clinical cancer research, 29(16), 3151-3161.
  24. DuVall AS, Wesevich A, Larson R (2023). Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Current hematologic malignancy reports, 18(6), 217-225.
  25. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer M (2023). Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica, 108(8), 2234-2239.
  26. DuVall AS, Sheade J, Anderson D, Yates SJ, Stock (2022). Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. JCO oncology practice, 18(7), 479-487.
  27. Maristany S, DuVall AS, Stock W, Adeleye A (2022). Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents. Journal of assisted reproduction and genetics, 39(8), 1733-1738.
  28. Alban J, DuVall A, Gurbuxani S, Stock W, Patel A (2022). Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO precision oncology, 6, e2200353.
  29. Bustinduy AL, Sutherland LJ, Chang-Cojulun A, Malhotra I, DuVall AS, Fairley JK, Mungai PL, Muchiri EM, Mutuku FM, Kitron U, King C (2015). Age-Stratified Profiles of Serum IL-6, IL-10, and TNF-¿ Cytokines Among Kenyan Children with Schistosoma haematobium, Plasmodium falciparum, and Other Chronic Parasitic Co-Infections. The American journal of tropical medicine and hygiene, 92(5), 945-51.
  30. DuVall AS, Fairley JK, Sutherland L, Bustinduy AL, Mungai PL, Muchiri EM, Malhotra I, Kitron U, King CH (2014). Development of a specimen-sparing multichannel bead assay to detect antiparasite IgG4 for the diagnosis of Schistosoma and Wuchereria infections on the coast of Kenya. Am J Trop Med Hyg, 90(4), 638-45.

Review

  1. Zhang A, Ji Q, Zhang K, Cao Q, Chen Y, Chen J, DuVall A (2022). Solution-focused brief therapy for adolescent and young adult cancer patients in China: a pilot randomized controlled trial. [Review]. J Psychosoc Oncol, 40, (6), 816-833.
  2. Decker M, Agarwal A, Benneche A, Churpek J, Duployez N, Duvall A, Ernst MPT, F�rster A, H�berg-Vetti H, Hofmann I, Nash M, Raaijmakers MHGP, Tvedt THA, Vlachos A, Schlegelberger B, Illig T, Ripperger T (2022). Validation and clinical application of transactivation assays for RUNX1 variant classification. [Review]. Blood Adv, 6, (11), 3195-3200.
  3. Zhang A, Kamat A, Acquati C, Aratow M, Kim JS, DuVall AS, Walling E (2022). Evaluating the Feasibility and Acceptability of an Artificial-Intelligence-Enabled and Speech-Based Distress Screening Mobile App for Adolescents and Young Adults Diagnosed with Cancer: A Study Protocol. [Review]. Cancers (Basel), 14, (4).
  4. Blumenstein KG, Brose A, Kemp C, Meister D, Walling E, DuVall AS, Zhang (2022). Effectiveness of cognitive behavioral therapy in improving functional health in cancer survivors: A systematic review and meta-analysis. Critical reviews in oncology/hematology, 175, 103709.
  5. Patel AA, Heng J, Dworkin E, Monick S, Derman BA, DuVall AS, Gurbuxani S, Kosuri S, Liu H, Thirman M, Godley LA, Odenike O, Larson RA, Stock W (2021). Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. [Review]. EJHaem, 2, (3), 413-420.
  6. Zhang A, Wang K, DuVall AS (2021). Examining the Pathoplastic Moderating Role of Education on the Association between Depressive Mood and Self-Rated Health among Cancer Survivors: A Population-Based Study. [Review]. Curr Oncol, 28, (5), 4042-4052.
  7. Schulte RR, Madiwale MV, Flower A, Hochberg J, Burke MJ, McNeer JL, DuVall A, Bleyer A (2018). Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. [Review]. Leuk Lymphoma, 59, (10), 2360-2368.

Case Report

  1. Michniacki TF, Hannibal M, Ross CW, Frame DG, DuVall AS, Khoriaty R, Vander Lugt MT, Walkovich KJ (2018). Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure. J Clin Immunol, 38(2), 166-173.

Letter

  1. Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow M (2024). Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood cancer journal, 14(1), 32.
  2. Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas MT, Drazer MW, DuVall AS, Kosuri S, Thirman MJ, Odenike O, Stock W, Larson RA, Patel A (2024). Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leukemia & lymphoma, 65(6), 864-867.